Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Are the Current Preclinical Models Adequate to Evaluate CAR-T Cell Therapy in Paediatric High-Grade Gliomas?

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Same author

Dual tumour-myeloid targeting of glioblastoma with GPNMB CAR-T cells.

Nature·2026

Same author

Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell function.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

TP63 expression correlates with mesenchymal-like gene signature in patient-derived recurrent glioblastoma cells.

Biochemical and biophysical research communications·2026

Same author

uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target.

Science translational medicine·2026

Same author

Generation of Allogeneic CAR-T Circumvents Functional Deficits in Patient-Derived Autologous Product for Glioblastoma.

International journal of cancer·2026

Search research articles

Related Experiment Video

Updated: Sep 20, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Targeted Radionuclide Therapy Using a Lutetium-177 Labeled Human Anti-CD133 Antibody.

Kevin Wyszatko¹, Nancy Janzen¹, Napoleon Law²

¹Department of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada.

Molecular Imaging and Biology

|May 22, 2025

Summary

Targeted radionuclide therapy using lutetium-177 labeled anti-CD133 antibody ([177Lu]Lu-DOTA-RW03) shows promise for treating refractory cancers. This therapy effectively targets cancer stem cells, reducing tumor growth and increasing survival in preclinical models.

Keywords:

CD133 Cancer stem cell Radioimmunotherapy Targeted radionuclide therapy

More Related Videos

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

Related Experiment Videos

Last Updated: Sep 20, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

Area of Science:

Nuclear medicine
Oncology
Immunotherapy

Background:

Cancer stem cells (CSCs) are implicated in tumor recurrence and treatment resistance.
Targeting CSC-specific markers like CD133 offers a strategy to eliminate these resilient cells.
Refractory tumors often harbor a significant CSC population, necessitating novel therapeutic approaches.

Purpose of the Study:

To synthesize and evaluate [177Lu]Lu-DOTA-RW03, a novel radioimmunoconjugate targeting CD133 for cancer therapy.
To assess the in vitro binding characteristics and in vivo biodistribution and efficacy of [177Lu]Lu-DOTA-RW03 in a CD133-expressing colorectal cancer model.

Main Methods:

Conjugation of a fully human anti-CD133 antibody (RW03) with DOTA-NHS and subsequent radiolabeling with Lutetium-177.
In vitro binding assays using CD133-expressing HT-29 cells to determine affinity and immunoreactivity.
In vivo biodistribution, SPECT imaging, and dose-escalation therapy studies in immunodeficient mice bearing HT-29 xenografts.

Main Results:

[177Lu]Lu-DOTA-RW03 was successfully synthesized with high radiochemical purity and yield, exhibiting excellent binding affinity and immunoreactivity.
Significant tumor uptake and favorable tumor-to-blood ratios were observed in vivo, with confirmed antigen specificity.
Dose-dependent therapeutic efficacy, including reduced tumor growth and increased survival, was demonstrated, alongside evidence of tumor necrosis.

Conclusions:

[177Lu]Lu-DOTA-RW03 demonstrates significant potential as an effective targeted radionuclide therapy for CD133-expressing cancers.
The findings support further investigation into [177Lu]Lu-DOTA-RW03 for multidosing and combination treatment strategies in refractory tumors.